The FPS Public Health and the FAMHP invite you to take part in the public inquiry on a clinical trial with genetically modified vaccines ChAdOx1-HPV and MVA-HPV against HPV infections (Human Papilloma Virus). The public inquiry runs from March 4, 2020 through April 3, 2020.
The clinical trial will be performed using female participants aged between 25 and 55 years, whereby persistant HPV infection and low-grade lesions in the cervical cells or «Cervical Lesions» were confirmed. The two test vaccines, developped by Vaccitech Ltd., have the goal of inducing a strong and long-lasting immune response by stimulating the body to increase the number of defence cells (or T-cells) in the blood. T-cells are very important in fighting an HPV infection.
The primary goal of this trial is to determine the safety of these two vaccines.
A single injection of each vaccine will be given 28 days apart.
The clinical trial will take place in the Brussels University Hospital, the Erasmus Hospital Brussels, the Ghent University Hospital and the Antwerp University Hospital.
As a citizen, you can give your opinion about this request for a clinical trial.
For each request for the use of a genetically modified organism in a clinical trial, the government organises a public inquiry lasting 30 days (under the Royal Decree dated February 21, 2005). For this you have access to various data from the application file and an online form (see Dutch or French) to make comments or ask questions.
The public inquiry runs through April 3, 2020.
General information at GGO- public inquiries (see Dutch or French).